Alisertib treatment in FANCA-deficient cell lines
Loss-of-function genomic alterations in FANCA occur across multiple cancer types, yet no molecularly targeted treatment options are available to exploit the loss of FANCA. We identified a vulnerability of FANCA-deficient cancers to AURKA inhibition. We observed that FANCA-loss leads to an upregulation and overexpression of AURKA in human cell lines and cancer tissue, supporting the observed vulnerability.
Loss-of-function genomic alterations in FANCA occur across multiple cancer types, yet no molecularly targeted treatment options are available to exploit the loss of FANCA. We identified a vulnerability of FANCA-deficient cancers to AURKA inhibition. We observed that FANCA-loss leads to an upregulation and overexpression of AURKA in human cell lines and cancer tissue, supporting the observed vulnerability.
University of Bern